Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Constellation Brands
STZ
US Stock MarketDetailed Quotes
KALA BIO (KALA)
- 5.475
- -0.225-3.95%
Close Jul 15 16:00 ET
- 5.475
- 0.0000.00%
Post 20:01 ET
35.33MMarket Cap-0.74P/E (TTM)
5.853High5.390Low80.26KVolume5.800Open5.700Prev Close447.86KTurnover2.18%Turnover RatioLossP/E (Static)6.45MShares11.20052wk High6.19P/B20.18MFloat Cap2.92052wk Low--Dividend TTM3.69MShs Float1337.500Historical High--Div Yield TTM8.11%Amplitude2.920Historical Low5.579Avg Price1Lot Size
KALA Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
KALA Orderflow
Unit: --
KALA Orderflow Trend
IntradayDayWeekMonth
No Data
KALA BIO (KALA) News
Ladenburg Thalmann Initiates KALA BIO(KALA.US) With Buy Rating, Announces Target Price $12
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
H.C. Wainwright Maintains KALA BIO(KALA.US) With Buy Rating, Maintains Target Price $12
$KALA Stock Is up 24% Today. Here's What We See in Our Data.
KALA BIO Shares Are Trading Higher After the Company Announced It Completed Patient Enrollment in the CHASE Phase 2b Clinical Trial Evaluating KPI-012.
KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial for KPI-012, Anticipates Topline Results by Q3 2025
KALA BIO (KALA) Stock Forum
$KALA BIO (KALA.US)$
KALA BIO To Highlight Potential Of KPI-012 For Treatment Of Persistent Corneal Epithelial Defect At Virtual Event On July 16 At 4 P.m. EST
KALA BIO To Highlight Potential Of KPI-012 For Treatment Of Persistent Corneal Epithelial Defect At Virtual Event On July 16 At 4 P.m. EST
1
$KALA BIO (KALA.US)$ KALA BIO Completes Enrollment In CHASE Clinical Trial Evaluating KPI-012 For Treatment Of Persistent Corneal Epithelial Defect! Topline Results From Chase Trial Expected by Q3 2025
2
1
1
$KALA BIO (KALA.US)$ KALA BIO To Highlight Potential Of KPI-012 For Treatment Of Persistent Corneal Epithelial Defect At Virtual Event On July 16 At 4 P.m. EST
1
Read more
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call